30-day FRN

3472

Federal Register / Vol. 84, No. 29 / Tuesday, February 12, 2019 / Notices

Dated: February 6, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–02011 Filed 2–11–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel Genomic Innovator.
Date: March 13, 2019.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, Greider Conference Room No. 3189,
6700B Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, 5635 Fishers
Lane, Suite 4076, Bethesda, MD 20814, 301–
594–4280, [email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)

amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Communication
Disorders Review Committee.
Date: June 20–21, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institure
on Deafness and Other Communication
Disorders, National Institute of Health, 6001
Executive Blvd., Rockville, MD 20850, 301–
402–3587, [email protected].
Name of Committee: Communication
Disorders Review Committee.
Date: October 17–18, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institure
on Deafness and Other Communication
Disorders, National Institute of Health, 6001
Executive Blvd., Rockville, MD 20850, 301–
402–3587, [email protected].
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: February 6, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.

provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel, P50
Clinical Trial Review.
Date: March 8, 2019.
Time: 1:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center Building (NSC), 6001
Executive Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health
Rockville, MD 20850, 301–402–3587, rayk@
nidcd.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: February 6, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–01971 Filed 2–11–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; International
Research Fellowship Award Program
of the (National Institute on Drug
Abuse)

Dated: February 6, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.

[FR Doc. 2019–01973 Filed 2–11–19; 8:45 am]

AGENCY:

BILLING CODE 4140–01–P

HHS.

[FR Doc. 2019–01969 Filed 2–11–19; 8:45 am]

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

BILLING CODE 4140–01–P

ACTION:

National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as

VerDate Sep<11>2014

18:30 Feb 11, 2019

Jkt 247001

National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the

PO 00000

Frm 00062

Fmt 4703

Sfmt 4703

National Institutes of Health,

Notice.

In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the National
Institute on Drug Abuse (NIDA),
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
SUMMARY:

E:\FR\FM\12FEN1.SGM

12FEN1

3473

Federal Register / Vol. 84, No. 29 / Tuesday, February 12, 2019 / Notices
Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
[email protected] or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.

ADDRESSES:

To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Dr. Steve Gust,
Director, NIDA International Program,
National Institute on Drug Abuse,
National Institutes of Health, 6001
Executive Blvd., Bethesda, Maryland
20892–0234, or call non-toll-free
number (301) 402–1118 or Email your
request, including your address to:
[email protected].

FOR FURTHER INFORMATION CONTACT:

This
proposed information collection was

SUPPLEMENTARY INFORMATION:

Award Program, 0925–0733, expiration
date 02/28/2019, REVISION, of the
National Institute on Drug Abuse
(NIDA), National Institutes of Health
(NIH).
Need and Use of Information
Collection: The purpose of this
information collection is to identify
participants for matriculation into the
program. The proposed information is
necessary to select the best applicants
for the fellowship program. An
application form to obtain information
about the potential fellows for
successful training in HIV and drug use
research is necessary. The information
ensures that fellows applying to these
programs meet eligibility requirements
for research and indicates their potential
as future scientists.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
60.

previously published in the Federal
Register on December 14, 2018, page
64348 (83 FR 64348–FR 64349) and
allowed 60 days for public comment. No
public comments were received. The
purpose of this notice is to allow an
additional 30 days for public comment.
The National Institute of Drug Abuse
(NIDA), National Institutes of Health,
may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
displays a currently valid OMB control
number.
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: The
International Research Fellowship

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents

Number of
responses per
respondent

Average time
per response
(in hours)

Total annual
burden hour

Type of respondent

Form

Applicant Scientists ...........................
Scientists ...........................................

Applicant Information .......................
Mentor Information ...........................

45
45

1
1

1
20/60

45
15

Total ...........................................

...........................................................

90

90

........................

60

Dated: February 4, 2019.
Genevieve deAlmeida,
Project Clearance Liaison, National Institute
on Drug Abuse, National Institutes of Health.
[FR Doc. 2019–02028 Filed 2–11–19; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which

VerDate Sep<11>2014

18:30 Feb 11, 2019

Jkt 247001

would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Toxicology and
Pharmacology.
Date: March 19, 2019.
Time: 1:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Terez Shea-Donohue,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2180,
MSC 7818, Bethesda, MD 20892,
[email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–18–
727: Molecular Profiles and Biomarkers of
Food and Nutrient Intake.
Date: March 19, 2019.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Gregory S. Shelness, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of

PO 00000

Frm 00063

Fmt 4703

Sfmt 4703

Health, 6701 Rockledge Drive, Room 6156,
Bethesda, MD 20892–7892, (301) 435–0492,
[email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Eukaryotic Parasites and Vectors.
Date: March 20–21, 2019.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Center
for Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person:Fouad A. El-Zaatari, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3186,
MSC 7808, Bethesda, MD 20892, (301) 435–
1149, [email protected].
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Biomedical Computing and Health
Informatics.
Date: March 20, 2019.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Ping Wu, Ph.D., Scientific
Review Officer, HDM IRG, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3166,

E:\FR\FM\12FEN1.SGM

12FEN1